Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KIFC1 | Q9BW19 | 11/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6891324 | 0.96 | TACR2 (0.44) | L3MBTL1KIFC1CTSSCTSKMMP8 | |
| SCHEMBL6898098 | 0.93 | OPRM1 (0.49) | KIFC1MMP8MMP2MMP9 | |
| SCHEMBL7753429 | 0.93 | OPRM1 (0.49) | KIFC1MMP8MMP2MMP9 | |
| SCHEMBL6898089 | 0.92 | MMP8 (0.42) | L3MBTL1KIFC1MMP8 | |
| SCHEMBL6890087 | 0.92 | AVPR1A (0.52) | L3MBTL1KIFC1MMP8 | |
| SCHEMBL27538326 | 0.92 | MMP8 (0.42) | L3MBTL1KIFC1MMP8 | |
| SCHEMBL6891355 | 0.92 | KIFC1 (0.45) | L3MBTL1KIFC1MMP8 | |
| SCHEMBL27538358 | 0.92 | AVPR1A (0.52) | L3MBTL1KIFC1MMP8 | |
| SCHEMBL6897535 | 0.91 | KMT2A (0.51) | KIFC1CTSSCTSKMMP9 | |
| SCHEMBL6898000 | 0.90 | MEN1 (0.43) | KIFC1CTSSCTSKMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | L3MBTL1 3448/4885KIFC1 4614/4885MME 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.